Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations

BRAF-V600 mutations occur in approximately 50% of patients with metastatic melanoma. Immune-checkpoint inhibitors and targeted therapies are both active as first-line treatments in these patients regardless of their mechanisms of action and toxicities. However, an upfront therapeutic strategy is sti...

Descripción completa

Detalles Bibliográficos
Autores principales: Giunta, Emilio Francesco, De Falco, Vincenzo, Napolitano, Stefania, Argenziano, Giuseppe, Brancaccio, Gabriella, Moscarella, Elvira, Ciardiello, Davide, Ciardiello, Fortunato, Troiani, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307282/
https://www.ncbi.nlm.nih.gov/pubmed/32612709
http://dx.doi.org/10.1177/1758835920925219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307282/
https://www.ncbi.nlm.nih.gov/pubmed/32612709
http://dx.doi.org/10.1177/1758835920925219

Ejemplares similares